Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1950 1
1952 3
1954 1
1955 1
1956 2
1957 2
1958 1
1959 1
1963 2
1964 4
1965 3
1966 2
1967 2
1970 1
1974 1
1978 1
1979 1
1980 2
1982 2
1983 3
1984 5
1985 1
1986 1
1987 1
1988 1
1989 1
1990 1
1991 1
1992 2
1997 1
2000 1
2001 4
2005 1
2007 1
2008 1
2015 2
2016 3
2017 2
2018 3
2019 1
2020 4
2021 4
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Chervin AS, Stone JD, Konieczna I, Calabrese KM, Wang N, Haribhai D, Dong F, White MK, Rodriguez LE, Bukofzer GT, Ellis PA, Cosgrove C, Hecquet C, Clarin JD, Palma JP, Reilly EB. Chervin AS, et al. Among authors: reilly eb. Mol Cancer Ther. 2023 Aug 1;22(8):903-912. doi: 10.1158/1535-7163.MCT-22-0770. Mol Cancer Ther. 2023. PMID: 37294945
Neglect, HPA axis reactivity, and development.
Reilly EB, Gunnar MR. Reilly EB, et al. Int J Dev Neurosci. 2019 Nov;78:100-108. doi: 10.1016/j.ijdevneu.2019.07.010. Epub 2019 Jul 30. Int J Dev Neurosci. 2019. PMID: 31374220 Review.
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Mhibik M, Gaglione EM, Eik D, Herrick J, Le J, Ahn IE, Chiu C, Wielgos-Bonvallet M, Hiemstra IH, Breij ECW, Chen J, Reilly EB, Epling-Burnette PK, Szafer-Glusman E, Sun C, Wiestner A. Mhibik M, et al. Among authors: reilly eb. Blood Adv. 2023 Aug 8;7(15):4089-4101. doi: 10.1182/bloodadvances.2022009517. Blood Adv. 2023. PMID: 37219524 Free PMC article.
HAEMATURIA AND ANTICOAGULANTS.
REILLY EB, PERRY A, FUJITA K, NAKAMURA RM. REILLY EB, et al. Lancet. 1964 Mar 7;1(7332):554. doi: 10.1016/s0140-6736(64)92940-x. Lancet. 1964. PMID: 14100201 No abstract available.
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Carneiro BA, Papadopoulos KP, Strickler JH, Lassman AB, Waqar SN, Chae YK, Patel JD, Shacham-Shmueli E, Kelly K, Khasraw M, Bestvina CM, Merrell R, Huang K, Atluri H, Ansell P, Li R, Jin J, Anderson MG, Reilly EB, Morrison-Thiele G, Patel K, Robinson RR, Aristide MRN, Gan HK. Carneiro BA, et al. Among authors: reilly eb. Neurooncol Adv. 2022 Dec 21;5(1):vdac183. doi: 10.1093/noajnl/vdac183. eCollection 2023 Jan-Dec. Neurooncol Adv. 2022. PMID: 36814898 Free PMC article.
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. Strickler JH, et al. Among authors: reilly eb. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4. J Clin Oncol. 2018. PMID: 30285518 Clinical Trial.
Lambda chains and genes in inbred mice.
Eisen HN, Reilly EB. Eisen HN, et al. Among authors: reilly eb. Annu Rev Immunol. 1985;3:337-65. doi: 10.1146/annurev.iy.03.040185.002005. Annu Rev Immunol. 1985. PMID: 3933530 Review. No abstract available.
85 results